MSI will showcase several standout flooring innovations at NeoCon, including the Studio LVT Collection, designed for exceptional durability, performance, and aesthetic appeal, alongside new colors from the McCarran® and Ladson® W Luxury Genuine Hardwood® Collections. The latest introductions feature three elegant herringbone designs that bring added sophistication and design flexibility to commercial environments. These thoughtfully engineered collections combine enduring style with installation-friendly formats tailored to the demands of today’s commercial spaces.

MSI will also debut its latest wall solutions, including Macro Wood Slat Panels and Reeded Wood Slat Panels. Designed to add warmth, texture, and architectural dimension, these innovative wall treatments deliver both aesthetic appeal and acoustic benefits for commercial interiors.

In addition, visitors can explore MSI’s newest Q Countertops introductions, including gorgeous Taj-Mahal inspired Ivoritaj, Serataj, Travataj, and Marfitaj, showcasing the effortless beauty of the iconic ivory-tone quartzite look. The new Calacatta Jadira and Calacatta Aravine surfaces will also be featured, with the stunning warm colors and veining of their marble-look design. Inspired by sought-after natural stone aesthetics, these surfaces combine timeless luxury with the durability and performance required for commercial applications.

“NeoCon provides an exceptional platform to showcase the latest innovations shaping commercial design,” said Al Pacheco, Executive Vice President of Marketing at MSI. “From our Studio Collection and new McCarran colors to our latest wood slat wall solutions and countertop introductions, these products reflect MSI’s commitment to delivering innovative, design-forward surfaces that help architects and designers create inspiring spaces.”

Join thousands from the commercial design industry at NeoCon 2026 and visit MSI to discover the latest trends, materials, and surface solutions redefining commercial interiors. Discover the quality, craftsmanship, and innovation that continue to make MSI a trusted partner for design professionals across North America.

About M S International, Inc. (MSI) 
Founded in 1975, MSI is a leading supplier of flooring, countertop, wall tile, and hardscaping products in North America. Headquartered in Orange, California, MSI maintains 50 state-of-the-art showrooms and distribution centers across the U.S. and Canada, with domestically sourced products for the Q Studio Collection in Latta, South Carolina, and Premium LVT in Cartersville, Georgia. MSI’s product assortment includes an extensive offering of engineered stone, LVT, tile, turf, natural stone, and porcelain products imported from over 37 countries on six continents.

To explore MSI’s complete range of products, visit www.msisurfaces.com.

Find us on Instagram, Facebook, and LinkedIn.

Media Contact:
Kristina Durkin
PR Coordinator
(404) 680-0220
Kristina.d@msisurfaces.com

THE MART MSI Contacts:

Mitchell Gomez
847-850-9506
mitchell@msisurfaces.com

Lio Giannotti
847-212-8662
lio.giannotti@msisurfaces.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/9ba59d7e-30b3-46e5-9e40-6ac1f8745bf4

https://www.globenewswire.com/NewsRoom/AttachmentNg/43a62c57-6986-4c35-bf07-06f9d39d3633

https://www.globenewswire.com/NewsRoom/AttachmentNg/da6c2f5f-341e-4da0-b5d3-c1d6aa21276c

https://www.globenewswire.com/NewsRoom/AttachmentNg/fdc4ec5a-4169-49c9-972f-4170e4993af5

BOSTON, June 02, 2026 (GLOBE NEWSWIRE) — Ataccama, the data trust company, today announced at Snowflake’s annual user conference, Snowflake Summit 26, new data product capabilities in Ataccama ONE that give enterprises a single, trusted, AI-ready version of the business data their teams and agents depend on. A Customer record, a Transaction, a Supplier, an Asset, each becomes a governed data product in Ataccama ONE with a clear owner, a verified definition, and an Ataccama Data Trust Index score that tells every team and AI agent whether that data is ready to use, delivered through Ataccama’s MCP Server into Snowflake CoCo, Cortex CoWork, and enterprise AI tools.

Most enterprises store data about the same thing in dozens of different systems, and those systems rarely agree. A Customer record in the CRM looks different from the one in the data warehouse, which looks different again from the one in the billing system. Definitions scatter across teams, governed inconsistently and duplicated across platforms, while modernization efforts and AI initiatives continue to widen those disconnects. Most data product programs improve ownership, discoverability, and context, helping teams understand what data means and where it comes from, but leave a more important question unanswered: whether the data can actually be trusted when decisions or AI agents depend on it. AI does not correct inconsistencies, gaps, or governance failures already embedded in the data environment. It amplifies them quickly, quietly, and at scale.

Ataccama ONE addresses this by organizing data around business meaning rather than physical storage. Organizations define the data that matters most, a Customer, a Transaction, a Supplier, an Account, as a trusted data product and connect it to every dataset that holds that information across their systems. Governance, ownership, and authoritative data sources apply at that level, creating a consistent business view of data across the enterprise. The Ataccama Data Trust Index continuously scores each data product across data quality, ownership completeness, and business context, giving people and AI agents a clear, evidence-based answer about whether data is fit for use at that moment. When AI tools access those data products through Ataccama’s MCP Server, they inherit governed business context and explainable Data Trust Index signals, turning governance into a trust layer the enterprise can build AI on with confidence.

“Knowing which version of a critical asset concept to trust, and being able to prove to our regulator that our answer is right, was the challenge that drove everything,” said Susan Spence, Senior Data Product Analyst, SSEN Transmission. “Being able to define what a critical concept like ‘substation’ means to the business, connect it to the right data, and see a clear signal of whether that data is fit for use is exactly the capability we needed. What we have built with Ataccama is the audit trail and the quality baseline that any future AI application will require, and that foundation gives us the confidence to move forward.”

Making trusted contextual data easily accessible is key for modern AI stacks. Ataccama is committed to invest in this data trust layer and is now joining the Open Semantic Interchange (OSI) as a collaborator, acting as a launch partner for Snowflake’s Agentic Data Sharing program, and deepening its integration with Snowflake CoCo and Cortex CoWork through Ataccama’s MCP Server. OSI alignment gives Ataccama’s data products a shared semantic foundation with other participants in the ecosystem, making them portable across the tools and platforms enterprises already use.

“Consistent semantics and governance are what make data products truly reusable across enterprise ecosystems,” said Josh Klahr, Head of Product Management at Snowflake. “Ataccama’s data products and OSI alignment ensure data can be understood, exchanged, and governed consistently across platforms, giving organizations a stronger foundation for AI at scale. Together, we are helping customers bring trusted, interoperable data directly into Snowflake so AI workflows can operate with the context, consistency, and reliability enterprise environments demand.”

“Most enterprises already have the data they need, but they still lack a reliable way to make that data trustworthy, interoperable, and usable wherever AI operates,” said Jay Limburn, Chief Product Officer at Ataccama. “Data products create the business-aligned foundation AI depends on, but when that foundation carries a verified trust signal and works natively inside platforms like Snowflake, governance becomes more than oversight. It becomes the infrastructure that allows AI to operate with confidence across the enterprise. That is the shift Ataccama is helping organizations make, because it is ultimately what determines whether AI delivers lasting business value at scale.”

Key capabilities:

• Business-Aligned Data Products. Organizations define the data that matters most to their business, a Customer, a Transaction, a Supplier, an Account, as a trusted data product and connect it to every dataset that holds that information across their systems. Ataccama applies ownership, business context, and criticality once at that level and propagates those controls automatically across every connected entity, so teams govern the definition once and apply it consistently everywhere it is used.
• Ataccama Data Trust Index Scoring. A weighted 0–100 trust score continuously measures data quality, ownership completeness, and business context, combining signals that most platforms manage across separate tools into a single, explainable result. People and AI agents can see exactly why a data product scores the way it does, replacing pass/fail indicators with an evidence-based view of fitness for use.
• MCP Server for Enterprise AI Workflows. Ataccama’s MCP Server delivers live Data Trust Index signals directly into AI tools and workflows so AI systems operate on verified, governed data from deployment onward. By exposing trusted data products directly through the MCP Server, Ataccama brings governed business context and trust signals into the agentic workflows and AI applications that depend on them.
• CoCo and CoWork Integration. Through Ataccama’s MCP Server, CoCo consumes Ataccama Data Trust Index scores to ground AI development in governed, verified data without moving it outside the Snowflake environment, giving CoCo and CoWork users direct access to trusted data products with embedded trust signals inside their AI workflows. Snowflake’s CoCo Accelerated Badge validates the integration for production-scale AI workloads.
• Agentic Data Sharing with Snowflake. As a launch partner for Snowflake’s Agentic Data Sharing program, Ataccama gives customers direct access to the data quality scores, governance signals, and observability findings it generates on their behalf, surfacing them in Snowflake through Cortex Agents, semantic views, and secure data sharing. Teams operationalize that intelligence across conversational and agentic workflows without building custom integration layers or moving data out of their environment.
• Open Semantic Interchange Participation. OSI alignment gives Ataccama an opportunity to define and share how trusted shared semantics should flow across participating platforms, enabling organizations to move semantics-serving data products across enterprise ecosystems without losing business meaning or creating vendor lock-in.

Ataccama will showcase these capabilities at Snowflake Summit, June 1-4, in San Francisco. Visit booth 2517 for live demonstrations and to speak with the team about building a data trust layer as the foundation for enterprise AI.

Ataccama will also join customer-led sessions throughout the event, including:

• Truist: How Truist Is Building the Data Foundation That Makes Cortex AI Possible
  June 3 at 2:30 p.m. PT | Session AR204

Additional information about Ataccama’s data products is available at www.ataccama.com.

About Ataccama
Ataccama provides the only end-to-end data trust platform that accelerates successful AI outcomes, mitigates risk, and powers data modernization with speed and scale. The Ataccama ONE platform is the essential data trust layer in the modern AI stack, sitting between data sources and AI orchestration to ensure every decision, model, and agent runs on accurate, governed, and trusted data. The platform unifies market-leading data quality and observability with catalog, lineage, and reference data to help organizations streamline their data management tech stack. The embedded ONE AI Agent acts as a digital data steward, continuously monitoring and improving data reliability, maximizing time-to-value, and team efficiency. Recognized as an Inc. Best Workplace for 2026 and a Leader in the 2026 Gartner Magic Quadrant for Augmented Data Quality, the 2026 Forrester Wave for Data Quality Solutions, and the 2025 Magic Quadrant for Data and Analytics Governance, Ataccama helps the world’s leading enterprises trust their data so they can accelerate AI. Learn more at www.ataccama.com.

Media contact

Lauren Ruth
Director of Global Communications
lauren.ruth@ataccama.com

According to S&P, Futu demonstrates strong market position in Hong Kong, and ongoing geographic diversification will help mitigate mainland China business phaseout over the next two years. S&P expects Futu’s very strong capitalization will remain a key strength underpinning the Company’s credit worthiness. Additionally, Futu will continue to uphold an adequate funding profile while it expands its business scope and geographic reach.

About Futu Holdings Limited

Futu Holdings Limited (Nasdaq: FUTU) is an advanced technology company transforming the investing experience by offering fully digitalized financial services. Through its proprietary digital platforms, Futubull and Moomoo, the Company provides a full range of investment services, including trade execution and clearing, margin financing and securities lending, and wealth management. The Company has embedded social media tools to create a network centered around its users and provide connectivity to users, investors, companies, analysts, media and key opinion leaders. The Company also provides corporate services, including IPO distribution, investor relations and ESOP solution services.

For investor inquiries, please contact:

Investor Relations
Futu Holdings Limited
ir@futuholdings.com

AUSTIN, Texas and AMSTERDAM, June 02, 2026 (GLOBE NEWSWIRE) — SEON, the AI Command Center for Fraud Prevention and AML Compliance, has built a platform where flexibility is an accent of its architecture. With SEON, customers can ingest any custom field or data type, build any rule or alert they need, and investigate in system driven workflows that represent the way their team operates. Most importantly, they can choose a rules-based policy, one driven by AI or a hybrid decisioning model that leverages both. SEON has the capabilities to meet teams how and where they actually operate.

Today, the company extends that same flexibility to the use of AI in the fight against fraud and financial crimes. A Model Context Protocol (MCP) server opens SEON’s data layer to whichever AI tool a team prefers. Two additional capabilities, Network Detection and AI Chart Builder, connect SEON’s existing capabilities in automation and business intelligence. To support adoption, an AI Playbook for Risk and Compliance Teams ships alongside them, giving customers a practical starting point for putting their MCP connection to work quickly.

Access to AI Has Outpaced Access to Risk Data
For most fraud and AML teams, AI is accessible but still hard to put to real work. Analysts have ChatGPT, Claude or Gemini at their fingertips. What they don’t have is a clean way to get their investigation data into those environments. Instead, they manually paste in transaction records, customer profiles and risk signals, losing context at every step and creating security risks for their organization. According to the 2026 Fraud and AML Leaders Report, 98% of fraud and AML leaders are already using AI in their workflows. The tools are there. The data pipeline is not.

An Open Foundation for Any AI Tool
SEON’s MCP server addresses that gap. Analysts can link Claude, ChatGPT, Gemini, Microsoft Copilot or any custom agent to SEON’s 900+ real-time risk signals spanning identity, device, behavioral, AML and IP data. All signals are accessible in a single call, so the AI spends its token budget and processing time on analysis rather than pulling data from multiple systems. Because the integration uses the open MCP standard, customers are free to use whatever works best today and switch to a stronger option tomorrow without rebuilding anything.

“The software world is moving toward a headless model, where teams don’t need to live inside a vendor’s dashboard to get full control over data and functionality,” said Tamas Kadar, CEO and Co-Founder, SEON. “Our job is to be the best command center for fraud, risk and compliance intelligence. We’re giving analysts the freedom to use whichever AI tools work best for them.”

“The SEON MCP integration has fundamentally changed how our risk analysts operate,” said Eric Taylor, Manager of Trust and Safety, TurboTenant. “Before, they had to manually pull data across multiple systems to piece together what happened. Now, we pull a user’s entire platform journey and all of SEON’s risk signal context directly into Claude, and AI connects the dots on complex fraud patterns without us doing that assembly. It’s opened up OSINT capabilities that wouldn’t have been possible before.”

Meeting Teams Where They Are
Some customers are ready to run their entire risk operation through an agentic platform. Others want AI working inside the SEON interface they already use. Most are somewhere in between. SEON supports all team preferences, whether they work inside the platform or outside it.

Network Detection builds on the network analysis SEON released last year, including Similarity ranking and the Network graph. It continuously scans the last two months of transactions across devices, emails, phone numbers and IP addresses to identify clusters that are only suspicious when viewed together. Coordinated fraud rings and money laundering networks now surface before an analyst opens an alert.

AI Chart Builder turns natural-language questions about your business into instant data visualizations. Analysts no longer wait on business intelligence teams for dashboard projects or are forced to rebuild reports from spreadsheet exports. They ask a question and the chart appears, built on live SEON data.

These join an AI portfolio SEON has shipped over the past year. Existing capabilities include AI-assisted rule creation, scoring insights, AML screening analysis, automated case summaries and regulatory report generation.

“The next generation of fraud and KYC challenges won’t look like the last one. AI agents will interact with our marketplaces as customers, and AI agents will be used to impersonate and exploit our customers as well. Our team needs an intelligence foundation that’s ready for both,” said Mostafa Hassanin, CISO, SMG Marketplace. “SEON opening its data layer to any AI we want to use is exactly the kind of architectural decision that fits where the market is going.”

A Fast-Start Kit for Teams Ready to Build
To help teams get started quickly, SEON is also releasing an AI Playbook for Risk and Compliance Teams. The playbook is a practical guide to connecting AI tools to SEON and building investigation workflows that match how analyst teams actually operate. It ships with pre-built agentic skills, including a fraud analyst daily briefing and a decline spot-check, both compatible with SEON’s MCP server and ready to deploy on day one.

The MCP server, Network Detection, AI Chart Builder and AI Playbook are available now to SEON customers.

About SEON
SEON is the AI command center for real-time fraud prevention and AML compliance, helping thousands of companies worldwide stop fraud, reduce risk and protect revenue. Powered by 900+ real-time, first-party data signals, SEON enriches customer profiles, flags suspicious behavior and supports both rules-based and AI-driven decisioning. With integrated fraud and AML capabilities, SEON operates globally from Austin, London, Budapest and Singapore. Learn more at seon.io.

Media Contact
press@seon.io

Chicago, IL, June 01, 2026 (GLOBE NEWSWIRE) — Drive Point Exchange, a leading auto finance platform renowned for its commitment to transforming the auto loan landscape, is thrilled to announce the expansion of its refinancing services to customers across the United States. This strategic move aims to empower more drivers with the ability to lower their monthly payments, refinance unfavorable loans, and secure better terms through a network of vetted lenders, dealers, and protection programs.

We dont just refinance we RECONSTRUCT!

With a focus on turning denials into approvals, Drive Point Exchange simplifies the refinancing process, ensuring that customers can navigate their options with ease and confidence. By leveraging its extensive network and innovative platform, the company is poised to make a significant impact on the financial well-being of drivers nationwide.

“Our mission has always been to provide drivers with the tools and resources they need to achieve financial freedom,” said Sean Gallagher, CEO of Drive Point Exchange. “By expanding our services nationwide, we are taking a monumental step towards helping more individuals unlock the benefits of refinancing, ultimately saving them money and enhancing their financial stability.”

“We are committed to making auto refinancing accessible and understandable for everyone,” Noor continued. “Our platform is designed to break down barriers and provide clear, actionable solutions that empower our customers to make informed decisions.”

Drive Point Exchange’s expansion is set to revolutionize the way drivers approach auto refinancing. By offering a streamlined process and personalized solutions, the company is dedicated to transforming the auto finance industry and setting a new standard for customer satisfaction.

As the company continues to grow, Drive Point Exchange remains steadfast in its mission to deliver exceptional service and innovative solutions to drivers across America. With its customer-centric approach and dedication to excellence, the company is well-positioned to lead the charge in the auto refinancing sector.

Press Inquiries

Sameenah Noor
contracts@drivepointexchange.com
18883510782
https://drivepointexchange.com
205 North Michigan Ave Suite 810, Chicago Il 60601

MCLEAN, Va., June 01, 2026 (GLOBE NEWSWIRE) — To kick off a month-long celebration of the 15-year anniversary of its founding, the Thought Leadership & Innovation Foundation (TLI) today announced the release of its new whitepaper, The Medicare Advantage Final Rule: A Defining Moment for O&P—and Why Data Will Decide Who Wins, alongside the pilot launch of the Limb Outcomes Voice (LOV), a new patient-centered outcomes platform designed to elevate the voice of individuals living with limb loss and limb difference.

Together, these initiatives represent a coordinated effort to help the orthotics and prosthetics (O&P) industry prepare for the accelerating shift toward value-based healthcare and outcomes-driven reimbursement.

The newly released whitepaper examines how the CMS Medicare Advantage Final Rule signals a broader transformation in healthcare policy—one that increasingly ties reimbursement, network participation, and provider value to measurable clinical outcomes and patient impact.

“The industry is entering a new environment where value can no longer simply be described—it must be demonstrated,” said Bill Oldham, Founder of the Thought Leadership & Innovation Foundation. “Outcomes data and patient-reported experiences are becoming essential infrastructure for the future of O&P.”

Central to the whitepaper is the growing importance of the Limb Loss and Preservation Registry (LLPR), which enables providers and researchers to systematically capture longitudinal outcomes data across the limb loss and limb preservation population.

At the same time, TLI is launching the pilot phase of Limb Outcomes Voice (LOV), a patient engagement and reporting platform designed to give individuals living with limb loss and limb difference direct access to meaningful insights about their mobility, function, quality of life, and health outcomes.

LOV allows participants to:

• Complete outcomes surveys and assessments
• View personalized reports and benchmark insights
• Access educational resources and support organizations
• Contribute their voice to a larger national outcomes effort

According to TLI, the connection between the CMS Final Rule, LLPR, and LOV is intentional.

“The future of healthcare will increasingly be shaped by real-world outcomes and patient experience,” Oldham said. “LOV helps ensure that the patient voice becomes part of the data infrastructure informing clinical care, policy decisions, and reimbursement models.”

The organization believes the combination of provider-driven registry data through LLPR and patient-reported insights through LOV creates a more complete picture of outcomes across the O&P continuum of care.

The whitepaper calls on O&P providers, manufacturers, researchers, and advocacy organizations to work collaboratively to strengthen outcomes measurement, improve data transparency, and ensure the profession plays an active role in defining how value is measured in the future healthcare landscape.

About the Thought Leadership & Innovation Foundation

The Thought Leadership & Innovation Foundation (TLI) is a nonprofit organization focused on advancing innovation, collaboration, and data-driven transformation across healthcare and rehabilitation. Through strategic initiatives, research partnerships, and technology-enabled platforms, TLI works to improve patient outcomes and strengthen the future of care for individuals living with limb loss and limb difference.

For more information, visit:
www.thoughtfoundation.org

Media Contact:
Thought Leadership & Innovation Foundation
info@thoughtfoundation.org

MUTSAMUDU, Comoros, June 01, 2026 (GLOBE NEWSWIRE) — MEXC, a leading 0-fee cross-asset trading platform, today announced the official launch of ‘RealStocks.’ This innovative equity product is now accessible to eligible users globally. The product seamlessly integrates real ownership rights of traditional financial assets with the low-friction experience of a crypto platform, further expanding MEXC’s 0-fee cross-asset trading ecosystem.

For a long time, investors looking to enter the U.S. stock market were limited to two less-than-ideal options. The first was trading through traditional brokerages, which requires enduring tedious currency exchange and deposit processes. The second was trading synthetic assets or tokenized products on crypto platforms, which often comes with drawbacks like poor liquidity and a lack of dividend payouts. The launch of ‘RealStocks’ breaks this deadlock, seamlessly bridging the gap between both worlds.

Building on a highly successful Beta phase validated by over 20,000 early users, the official launch ensures a seamless, battle-tested trading experience. Through MEXC’s licensed broker partner, eligible users can purchase shares in real U.S. listed companies, with genuine market exposure and liquidity consistent with traditional U.S. equity markets. Where applicable, users are entitled to dividends or distributions on their holdings. The entire trading flow is integrated into MEXC’s existing interface. Users transact in USDT, making the experience of buying U.S. stocks similar to buying crypto in practice. Trading hours follow Nasdaq market sessions, and zero platform trading fees apply during the launch period, keeping costs to a minimum. The product has been validated by over 20,000 users during Beta phase.

MEXC is simultaneously launching three limited-time incentive campaigns.
Campaign 1: SpaceX(PRE) Airdrop Reward (May 28 – June 5)
Complete a U.S. stock spot trade and participate in the SpaceX(PRE) Season 2 Launchpad subscription before it closes, and receive additional SpaceX(PRE) airdrop rewards. Total prize pool: 200,000 USDT equivalent. Maximum reward per user: 5,000 USDT equivalent in SpaceX(PRE).
Campaign 2: $1,000,000 Stock Prize Pool (June 2 – June 16)
During the campaign period, U.S. stock spot trading is available at zero fees. Complete trading tasks to share in a 1,000,000 USD equivalent stock prize pool.
Campaign 3: Real-Time Market Data Subsidy for New Deposits (First month after U.S. stock launch)
Complete a qualifying deposit to receive a real-time market data subsidy — helping users start trading U.S. stocks with zero barrier to entry.

MEXC CEO Vugar Usi said:
“From Pre-IPO access to tokenized stocks, and now to real share ownership through U.S. stock spot trading, MEXC has continuously pushed the boundaries of what crypto users can access in global markets. With U.S. stock spot trading, users can now truly own world-class traditional financial assets within a familiar crypto trading environment — not just track their price. As 2026 brings a historic wave of IPO windows from the world’s top technology companies, crypto users will have the chance to participate as real shareholders for the first time. This is what Infinite Opportunities means at MEXC — not a tagline, but a product.”

‘RealStocks’ is now live and open to eligible users. Log in to MEXC and start trading U.S. stocks.

About MEXC
MEXC is the world’s fastest-growing cryptocurrency exchange, trusted by more than 40 million users across 170+ markets. Built on a user-first philosophy, MEXC offers industry-leading 0-fee trading and access to over 3,000 digital assets. As the Gateway to Infinite Opportunities, MEXC provides a single platform where users can easily trade cryptocurrencies alongside tokenized assets, including stocks, ETFs, commodities, and precious metals.
MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC

Disclaimer
“0 fees” refers only to the platform’s service charge. Users may still be subject to certain fees, including but not limited to SEC transaction fees, FINRA trading activity fees (TAF), exchange and market center fees, regulatory fees, and any applicable clearing fees.
Not investment advice. For informational purposes only. Trading involves risk. Please consult a qualified professional before making any investment decision.
Territorial Limit: This service is offered only to users in certain jurisdictions. Access may be restricted in certain countries or regions due to local laws and regulations. Please refer to our Terms & Conditions for the complete list of eligible jurisdictions.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fba1558b-9699-483a-85f0-1d78cc2471b3

CONTACT: For media inquiries, please contact MEXC PR team: media@mexc.com

The $1.43 million milestone gives AlphaPepe a clear company update as Ethereum price prediction headlines return to higher upside targets, with bullish ETH forecasts pointing toward $10,000 if ETF demand, institutional adoption, stablecoin growth, and on-chain activity continue to strengthen.

AlphaPepe Hits $1.43M as Stage 17 Advances

AlphaPepe crossing $1.43 million marks another important milestone in the project’s presale trajectory. Stage 17 is active at $0.01822, and the holder count has now passed 9,100 before public trading begins. That continued growth shows the presale is building beyond early launch attention and moving through stage progression, community expansion, and product development ahead of the planned Q2 2026 exchange debut.

The stage-based structure gives participants a visible path as the launch window tightens. Each stage transition brings the next scheduled pricing step closer, while token delivery remains instant with no vesting and no claim delay. That removes one of the most common friction points seen across early-stage launches.

AlphaPepe’s product layer continues to support the presale momentum. AlphaSwap, the project’s AI-powered decentralized exchange, has already surpassed 5,000 active demo users. That gives the project a working product environment before its exchange debut, separating it from many presales that enter public markets with only a roadmap.

AlphaSwap includes AI contract screening, whale wallet tracking, and cross-chain execution on BSC. The contract screening layer is designed to detect risky token behavior before users interact with a smart contract. The whale tracking layer gives traders visibility into large wallet movements as they happen. The cross-chain execution layer is being built to make meme coin trading faster and less fragmented.

The 10/10 BlockSAFU audit adds another layer of credibility before the token reaches exchanges. Combined with 9,100+ holders, over $1.43 million raised, Stage 17 momentum, 5,000 demo users, and instant token delivery, AlphaPepe is building a stronger pre-listing profile than many early-stage meme projects in the current cycle.

Ethereum Price Prediction Eyes $10K

The Ethereum price prediction debate has returned to higher upside targets, with bullish forecasts pointing toward $10,000 if ETF demand, institutional adoption, stablecoin growth, and stronger on-chain activity continue to support ETH. Standard Chartered has also raised long-term Ethereum targets before, citing stablecoin expansion, Ethereum network usage, and ETH’s role in traditional finance as key drivers.

The $10,000 Ethereum price prediction remains a bullish scenario, not a guaranteed outcome. For AlphaPepe, the nearer story is internal execution, with Stage 17 active at $0.01822, over $1.43 million raised, AlphaSwap already tested by more than 5,000 demo users, and the Q2 2026 exchange debut still moving closer.

Conclusion

AlphaPepe’s latest update gives the project a defined company milestone while broader crypto traders continue watching Ethereum price prediction targets. The presale has crossed $1.43 million, Stage 17 is live at $0.01822, the holder count has passed 9,100, and AlphaSwap has already surpassed 5,000 active demo users.

The $10,000 Ethereum price prediction shows how aggressive upside narratives are still shaping crypto market attention when ETF demand, institutional adoption, stablecoin growth, and on-chain activity are part of the story. But AlphaPepe’s roadmap is unfolding on a shorter timeline, with presale progression, product testing, audit completion, and exchange preparation all converging in the same quarter.

For participants tracking early-stage crypto opportunities, the current setup is clear. AlphaPepe has capital raised, holder growth, working product traction, audit credibility, instant token delivery, and Q2 exchange timing moving together. Stage 17 remains active at $0.01822, with the next visible milestones tied to AlphaSwap’s full launch and public exchange access.

CLICK TO VISIT ALPHAPEPE OFFICIAL WEBSITE

FAQs

What is AlphaPepe’s current presale status?
AlphaPepe has raised over $1.43 million, Stage 17 is live at $0.01822, and the holder count has passed 9,100. The AlphaSwap AI DEX demo has also surpassed 5,000 active users, and the project has completed a full 10/10 BlockSAFU audit ahead of its planned Q2 2026 exchange debut.

What is the $10K Ethereum price prediction?
The $10K Ethereum price prediction refers to a bullish scenario where ETH reaches $10,000 if ETF demand, institutional adoption, stablecoin growth, and stronger Ethereum network activity continue to build. It remains a forecast scenario, not a guaranteed outcome.

About AlphaPepe
AlphaPepe is building AlphaSwap, an AI-powered decentralized exchange designed to make on-chain meme coin trading safer, faster, and more transparent. The platform includes AI contract screening, whale wallet tracking, and cross-chain execution on BSC, giving traders additional tools before interacting with early-stage tokens.

AlphaPepe has raised over $1.43 million in its presale, passed 9,100 holders, surpassed 5,000 active AlphaSwap demo users, and completed a full 10/10 BlockSAFU security audit. Stage 17 is live at $0.01822, with instant token delivery, no vesting, no claim delay, and a planned Q2 2026 exchange debut.

Contact:
Jack Duffy
contact@alphapepe.io

Disclaimer: This content is provided by AlphaPepe. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.

Legal Disclaimer: This media platform provides the content of this article on an “as-is” basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2345b46c-6f5a-4acf-9291-953aff4a6879

Houston, Texas and Tuebingen, Germany, May 31, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced the presentation of extended data from the ongoing Phase 1 clinical trial evaluating its TCR bispecific (TCER^®) candidate IMA401 targeting MAGEA4/8 in heavily pretreated patients with solid tumors, including head and neck cancer and lung cancer, in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA. The data show a consistent and favorable tolerability profile across multiple tumor types and encouraging anti-tumor activity at the recommended Phase 2 dose (RP2D) with or without the immune checkpoint inhibitor (ICI) pembrolizumab. Results from the Phase 1 study are being published simultaneously in Nature Medicine.

Data from the ongoing Phase 1 study of IMA401 will be presented on May 31, 2026, during the Developmental Therapeutics Session – Immunotherapy from 8:00-11:00 am CDT by Martin Wermke, M.D., TU Dresden University of Technology, NCT/UCC Early Clinical Trial Unit, Dresden, Germany (Abstract ID: 2507). The slides are available in the ‘Events & Presentations’ section of the Investor & Media page on the Company’s website.

Carsten Reinhardt, M.D., Ph.D., Chief Development Officer at Immatics, said, “The IMA401 clinical data represent an important step forward for our next-generation, off-the-shelf TCER^® platform and reinforce the potential of this modality to address both advanced and earlier-stage solid tumors. Building on the encouraging clinical activity and supportive preclinical findings, we believe IMA401 may have even greater potential in combination with IMA402, our PRAME-directed bispecific. The initiation of the IMA401/IMA402 combination cohort in squamous cell non-small cell lung cancer marks a milestone toward broadening patient reach and delivering meaningful clinical benefit for patients with significant unmet needs.”

Based on the clinical data for IMA401, including the initial clinical signal in squamous cell non-small cell lung cancer (sqNSCLC), as well as preclinical proof-of-concept data and clinical data for IMA402, Immatics has initiated enrollment in a Phase 1 cohort at multiple clinical trial sites evaluating IMA401 targeting MAGEA4/8 in combination with IMA402 targeting PRAME in sqNSCLC. The dual targeting approach is designed to broaden patient coverage and potentially enhance anti-tumor activity by addressing two highly prevalent cancer targets, with sqNSCLC as the first indication, and further development potential for many others. Based on combined target prevalence, more than 90% of patients with sqNSCLC express PRAME and/or MAGEA4/8. The current addressable patient population for metastatic sqNSCLC in the United States and EU5 is estimated at approximately 40,000 patients per year. First data from the IMA401/IMA402 combination cohort are expected in 2027.

Highlights of Immatics’ clinical data on IMA401

Patient population: Heavily pretreated, highly heterogeneous patient population

• As of the data cutoff on March 2, 2026, 61 patients with recurrent and/or refractory solid tumors across >15 different tumor types were treated with IMA401 with or without an immune checkpoint inhibitor (ICI, pembrolizumab) in a Phase 1 dose-escalation basket trial (NCT05359445).
• Patients were heavily pretreated with a median of three prior lines of systemic treatment (range: 1-8).
• 44 patients were treated at RP2D (1-2 mg), with 32 receiving monotherapy and 12 receiving the combination of IMA401 and pembrolizumab. Among these patients, head and neck cancer represented the largest subgroup treated at RP2D (n=14).

Safety: Favorable tolerability at RP2D supporting broad combinability of IMA401

• The tolerability profile of IMA401 with or without pembrolizumab was consistent across patient populations.
• The most frequent clinically relevant treatment-related adverse events (TRAE) observed across dose levels were low-grade cytokine release syndrome (CRS) (38% G1-2, no ≥ Grade 3), expected and transient lymphopenia (33%), consistent with the mechanism of action, and neutropenia (31%). Within the RP2D range of 1-2 mg, neutropenia was mostly transient and manageable.
• Notably, no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.
• Tolerability of IMA401 at RP2D in combination with pembrolizumab was consistent with IMA401 as a monotherapy at RP2D, with no overlapping and/or additive toxicity observed.
• Tolerability profile of IMA401, both as a monotherapy and with pembrolizumab, supports broad combination potential of IMA401.

Anti-tumor activity and durability: Promising clinical activity with deep and durable responses
Patients treated with IMA401 at RP2D as a monotherapy or in combination with pembrolizumab demonstrated clinical activity across multiple solid tumor indications, including melanoma, sqNSCLC, head and neck cancer and others:

• Head and neck cancer (largest patient subgroup treated at RP2D): confirmed objective response rate (cORR) of 29% (4/14), disease control rate (DCR) of 64% (9/14), median duration of response (mDOR) of 8.8 months. The 12-month overall survival (OS) rate was 63% and the six-month progression-free survival (PFS) rate was 43%. All responders achieved deep tumor reduction ranging from 60-100% and three of four responders were ongoing at data cutoff.
• Melanoma: cORR of 33% (2/6), DCR of 67% (4/6); both confirmed responses lasted beyond six months post treatment, with one ongoing for >2.5 years.
• sqNSCLC: A presented patient case highlighted a patient with ICI-resistant sqNSCLC who received IMA401 plus pembrolizumab in fifth-line (prior best overall response: stable disease) and achieved a partial response with shrinkage of all target lesions.

^a Two patients not shown in plot due to clinical progression before post-infusion scan. ^b One patient not shown in plot due to clinical progression before post-infusion scan. BL: Baseline; BOR: Best overall response; (c)PR: (confirmed) partial response; H&N: head and neck cancer; PD: progressive disease; RECIST: response evaluation criteria in solid tumors; SD: stable disease.

Preclinical data: Supporting broad patient coverage and potential synergistic activity of IMA401/IMA402 combination

• Target expression data from analyzed tumor samples showed that >90% of patients with sqNSCLC are positive for PRAME and/or MAGEA4/8, and ~60% of patients with sqNSCLC are positive for both targets, suggesting that a combination therapy against both targets could boost anti-tumor activity and counteract potential tumor escape mechanisms.
• IMA401/IMA402 combination demonstrated synergistic anti-tumor activity in MAGEA4/8 and PRAME double-positive tumor cell lines.

Data on the IMA401 Phase 1 trial are published simultaneously in Nature Medicine.

About Immatics TCR Bispecifics (TCER^®)
Immatics’ next-generation half-life extended TCER^® molecules are antibody-like “off-the-shelf” biologics that leverage the body’s immune system by redirecting and activating T cells towards cancer cells expressing a specific tumor target. The design of the TCER^® molecules enables the activation of any T cell in the body to attack the tumor, regardless of the T cells’ intrinsic specificity. Immatics’ proprietary biologics are engineered with two binding regions: a TCR domain and a T cell recruiter domain. The TCER^® format is designed to maximize efficacy while minimizing toxicities in patients. It contains a high-affinity TCR domain that is designed to bind specifically to the cancer target peptide on the cell surface presented by an HLA molecule. The antibody-derived, low-affinity T cell recruiter domain is directed against the TCR/CD3 complex and recruits a patient’s T cells to the tumor to attack cancer cells. With a low-affinity recruiter aiming for optimized biodistribution and enrichment of the molecule at the tumor site instead of the periphery, TCER^® are engineered to reduce the occurrence of immune-related adverse events, such as cytokine release syndrome. In addition, the TCER^® format comprises an Fc part that confers half-life extension, stability, and manufacturability. TCER^® molecules are “off-the-shelf” biologics and thus immediately available for patient treatment. They can be distributed through standard pharmaceutical supply chains and can reach a large patient population without the need for specialized medical centers.

About IMA401 MAGEA4/8 Bispecific
IMA401 is a molecule from Immatics’ TCR bispecifics pipeline that targets an HLA-A*02:01-presented peptide derived from two different cancer-associated proteins, melanoma-associated antigen 4 and/or 8 (“MAGEA4/8”). The MAGEA4/8 peptide has been identified and validated by Immatics’ proprietary mass spectrometry-based target discovery platform XPRESIDENT^® and is presented at a 5-fold higher target density (copy number per tumor cell) than the MAGEA4 peptide targeted in other clinical trials. IMA401 is currently being evaluated in a Phase 1 basket trial in patients with MAGEA4/8-positive solid tumors. The MAGEA4/8 peptide has a high prevalence in several solid tumor indications such as head and neck squamous cell carcinoma (HNSCC), squamous cell non-small cell lung cancer (sqNSCLC), as well as melanoma and other solid cancer types.

About IMA402 PRAME Bispecific
IMA402 is a molecule from Immatics’ TCR bispecifics (TCER^®) pipeline directed against an HLA-A*02:01-presented peptide derived from PRAME. IMA402 is currently being evaluated in a Phase 1 trial in patients with solid tumors expressing PRAME. IMA402 is part of Immatics’ strategy to leverage the full clinical potential of targeting PRAME, one of the most promising targets for TCR-based therapies.

About Immatics
Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.

Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedIn and Instagram.

Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, observations from the Company’s clinical trials, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing of IND, CTA or BLA filings, estimated market opportunities of product candidates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification.

For more information, please contact:

Media
Trophic Communications
Phone: +49 151 74416179
immatics@trophic.eu

Immatics N.V.
Jordan Silverstein
Head of Strategy
Phone: +1 346 319-3325
InvestorRelations@immatics.com 

Attachment

• PDF Version

LOS ANGELES, May 31, 2026 (GLOBE NEWSWIRE) — Crypto markets have been moving with a speed that’s catching many traders off guard. What used to be steady trend cycles has shifted into sudden, sharp swings — and Bitcoin has been leading that shift.

BTC/USD came under heavy pressure this week after a rejection near $77,000, triggering a fast pullback that even pushed the pair briefly below $73,000. Analysts point to month‑end rebalancing, thinning liquidity, and rapid ETF‑driven flows as the main forces behind the latest volatility heading into June 2026.

With intraday ranges widening and sentiment turning on a single headline, traders are finding it harder to react quickly enough. That pressure is pushing more market participants toward automated tools that can keep up with the pace of these fast‑moving conditions.

AIX Alpha Launches a New AI‑Driven Quant System

AIX Alpha this week introduced a new automated trading system designed to make quantitative strategies more accessible to everyday users. As part of the rollout, eligible new users may receive a $10 welcome bonus after completing onboarding. Terms and conditions apply.

The platform combines data‑driven analysis, automated execution, and multi‑strategy coordination within a single interface built for 24/7 digital asset markets. According to the company, the system processes more than 100,000 market signals per day across major assets including BTC, ETH, XRP, SOL, and BNB.

Rather than relying on fixed indicators, AIX Alpha’s models adjust dynamically as market conditions shift — a feature the company says is increasingly important as volatility accelerates into mid‑2026.

System Overview

AIX Alpha currently supports more than ten quantitative strategies, including:

• Adaptive Market Neutral Strategy
• Market Timing Strategy
• Multi‑Factor Strategy
• Neural Signal Execution Strategy

All strategies operate within a unified, risk‑aware framework designed for continuously moving markets.

Why Traders Are Paying Attention

The recent surge in volatility has highlighted the limits of manual trading. Sudden liquidity gaps, ETF‑driven flows, and macro‑sensitive sentiment have made it harder for individuals to react in time.

Automated systems, by contrast, can respond instantly — a key advantage when markets move in seconds rather than minutes.

A spokesperson for AIX Alpha said the company aims to “make digital asset participation simpler and more accessible as markets become more fast‑paced.”

Getting Started

New users can create an account, choose a strategy configuration, and enable automated execution.
As part of the current promotion, eligible registrants may also receive a $10 welcome bonus upon completing onboarding. Terms apply.

More information is available on the official AIX Alpha website: [ AixAlpha.net ]

Disclaimer: This article is for informational purposes only and does not constitute investment, financial, or trading advice. Digital asset markets involve risks and may experience significant volatility.

CONTACT: AIX Alpha Public Team AIX Alpha https://aixalpha.net info@aixalpha.net